Contaminated Drugs Prompt FDA Request for Manufacturing Audits

Sept. 1, 2020, 9:10 PM

Drug companies should audit their ingredient supply chains and manufacturing processes to protect consumers from potentially cancer-causing agents, the FDA said Tuesday after investigating several types of popular medicines that contained carcinogens.

The policy focuses on nitrosamine, which at high levels could can cause cancer in humans. A spate of high-profile drug recalls over the past couple of years spotlighted quality control issues in some types of drugs. The recalls included a popular heart-burn medicine commonly known as Zantac, which the FDA pulled from shelves permanently in April.

The contamination concern extends to some of the biggest names in the ...

To read the full article log in.

Learn more about A Bloomberg Law subscription.